#ClinicSpeak: mode of action of B cell therapy in MS

What is missing from the anti-B-cell narrative? #ClinicSpeak #MSBlog

Will anti-B-cell therapies become the agents of choice for treating both the relapsing and advanced stages of MS. Another slick video explaining the mode of action of anti-B-cell therapies. 

What is missing? I think the narrative in this video is incomplete. Can you spot was is missing? 

CoI: multiple, the production of this video has been funded by Roche

Labels: , ,